Biotech · Private company · South San Francisco, CA, US

Akero Therapeutics, Inc.

SEC CIK 0001744659

Track this companyFree. Adds Akero Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials63 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline4

EfruxiferminPhase 3 · NASH/MASHClinicalTrials.gov · fetched Nov 12, 2026
EfruxiferminPhase 3 · NASH - Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
EfruxiferminPhase 3 · NASH With FibrosisClinicalTrials.gov · fetched Nov 12, 2026
EFXPhase 2 · NASH - Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPHASE3 · RECRUITING · started Oct 4, 2024ClinicalTrials.gov NCT06528314 · fetched Nov 12, 2026
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisPHASE3 · RECRUITING · started Dec 1, 2023ClinicalTrials.gov NCT06215716 · fetched Nov 12, 2026
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)PHASE3 · ACTIVE_NOT_RECRUITING · started Nov 10, 2023ClinicalTrials.gov NCT06161571 · fetched Nov 12, 2026
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)PHASE2 · COMPLETED · started Jul 30, 2021ClinicalTrials.gov NCT05039450 · fetched Nov 12, 2026
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)PHASE2 · COMPLETED · started Feb 16, 2021ClinicalTrials.gov NCT04767529 · fetched Nov 12, 2026
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)PHASE2 · COMPLETED · started May 28, 2019ClinicalTrials.gov NCT03976401 · fetched Nov 12, 2026